Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

A Prospective, Double-Blind, Randomized, Parallel- Group, Dose-Ranging Study of Botulinum Toxin Type A in Female Subjects With Horizontal Forehead Rhytides

CARRUTHERS, ALASTAIR, MD*; CARRUTHERS, JEAN, MD; COHEN, J., MD*

ORIGINAL ARTICLES
Buy
SDC

BACKGROUND Botulinum toxin type A is used cosmetically to improve facial lines, but it has not been thoroughly investigated for the treatment of horizontal forehead rhytides.

OBJECTIVE To compare the efficacy and safety of three doses of botulinum toxin type A in females with horizontal forehead rhytides and to establish whether the response rate and the duration of response are dose dependent.

METHODS Fifty-nine female patients with horizontal forehead rhytides scoring 2 (moderate) or 3 (severe) on the facial wrinkle scale (FWS) were randomly assigned to receive 16, 32, or 48 U of botulinum toxin type A (Botox, Botox Cosmetic; Allergan, Irvine, CA), which was administered to eight injection sites. Half of the dose was administered to the brow depressors and the other half to the elevators. Wrinkle severity was assessed by the investigator and patient using the FWS at baseline, at Weeks 2 and 4, and then every 4 weeks for 48 weeks.

RESULTS Improvements in horizontal rhytides were observed in all dosage groups. Significant dose–response trends were observed for rate of improvement at maximum brow elevation (53% in the 48-U group vs. 15% in the 16-U group at 16 weeks) and rate of relapse to baseline (35% in the 48-U group vs. 75% in the 16-U group at 16 weeks) by a trained observer.

CONCLUSION Higher botulinum toxin type A doses resulted in greater efficacy and longer duration of effect in the reduction of horizontal rhytides.

*Division of Dermatology, Vancouver, British Columbia, Canada

Department of Ophthalmology, Vancouver, British Columbia, Canada

Address correspondence and reprint requests to: Alastair Carruthers, MD, 943 West Broadway, Suite 820, Vancouver, BC V5Z 4E1, Canada, or e-mail: alastair@carruthers.net

DRS. CARRUTHERS ARE CONSULTANTS TO ALLERGAN, AND SUPPLIES FOR THIS STUDY WERE PROVIDED BY ALLERGAN.

© 2003 by the American Society for Dermatologic Surgery, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website